Federal heat on UnitedHealth sends shares tumbling — what you need to know

UnitedHealth Group Inc. (NYSE: UNH) saw its stock tumble nearly 4% today, continuing a steep downward spiral that has erased over 40% of its value in 2025 alone. The latest drop comes after the company confirmed that it’s under both criminal and civil investigation by the U.S. Department of Justice (DOJ), related to its Medicare Advantage billing practices.

How much has UnitedHealth stock lost in 2025?

UnitedHealth stock has been among the worst performers on the S&P 500 this year. After starting 2025 near $525 per share, the stock has plummeted below $300, marking a more than 40% year-to-date drop.

Key moments behind the plunge:

• April 2025: Stock dropped 22% in a single day after missing Q1 earnings and slashing full-year guidance.
  
  
• May 2025: CEO Andrew Witty resigned, adding leadership instability to the mix.
  
  
• July 2025: Confirmation of DOJ investigation triggers renewed selling pressure.

UnitedHealth Under DOJ Investigation: What’s Going On?

The Department of Justice (DOJ) is officially investigating UnitedHealth Group—America's largest health insurer—over its Medicare Advantage billing. The federal probes focus on whether the company artificially inflated patient risk scores to receive higher reimbursements from the government.

UnitedHealth has confirmed receiving requests for information from the DOJ and stated it is cooperating fully with both criminal and civil investigations. While the company initially denied any criminal probe, it now admits it had proactively reached out to federal authorities earlier this year to clarify billing procedures and launch internal reviews.

The DOJ’s primary concern is centered on risk adjustment coding—a process that determines how much money the federal government pays insurers like UnitedHealth based on patients' medical conditions. Allegations suggest the company may have exaggerated diagnoses to collect excess payments from Medicare.

How Did the Market React?

As soon as news of the investigation surfaced, UnitedHealth stock took a hit. Shares fell over 4% in premarket trading, extending a broader decline that’s seen the stock drop more than 40% year-to-date.

This is not an isolated event. Earlier this year, UnitedHealth's stock experienced a major downturn when its former CEO unexpectedly resigned and the company withdrew its 2025 earnings guidance, citing cost overruns tied to its Medicare Advantage business.

The current legal troubles are piling onto existing financial pressures, sending a clear message to investors: the road ahead may be rocky.

The Core Issue: Medicare Advantage Risk Adjustment

At the heart of the investigation is Medicare Advantage, a privately managed health insurance program funded by the federal government. Insurers like UnitedHealth receive payments based on the health risk profiles of their enrollees.

The more serious the health conditions of a patient, the higher the risk score—and the larger the government payout. However, the DOJ is now investigating whether UnitedHealth manipulated these scores by inflating patient diagnoses.

This isn’t a new concern in the industry. Other insurers have faced similar audits and lawsuits. However, given UnitedHealth’s size and influence, the implications could be significantly larger.

Is it time to buy the dip on UnitedHealth stock?

This is the big question facing investors. UNH stock may look cheap relative to historical valuation, but headline risk remains high. Here are two opposing scenarios:

Bull Case:

• DOJ investigation ends with a manageable settlement.
  
  
• Medical cost inflation stabilizes.
  
  
• Leadership transition brings strategic clarity.
  
  

Bear Case:

• Legal issues expand and trigger major fines or contract losses.
  
  
• Costs continue rising, forcing more earnings cuts.
  
  
• Institutional investors exit further, adding pressure.

UnitedHealth’s Response: Transparency, Audits & Reforms

In response to the federal heat, UnitedHealth has taken several steps to present itself as compliant and transparent:

• Voluntary Disclosures: The company claims it initiated contact with the DOJ months ago and is cooperating with all requests.
  
  
• Third-party Audits: UnitedHealth says it is conducting external reviews of its risk adjustment processes, possibly signaling internal reforms are underway.
  
  
• Compliance Enhancements: The insurer is working on strengthening its internal controls to ensure billing accuracy going forward.
  
  

Despite these efforts, legal experts suggest that even if no wrongdoing is found, the very existence of a federal investigation could lead to increased regulatory oversight, reputational damage, and mounting legal expenses.

Other Headwinds Facing UnitedHealth

The DOJ probe comes at a time when UnitedHealth is already navigating several internal and external challenges:

1. Leadership Shake-Up

In May, longtime CEO Andrew Witty stepped down unexpectedly amid the growing storm. Former CEO Stephen Hemsley returned to stabilize the company and restore investor trust.

2. Rising Medical Costs

Healthcare utilization surged in recent quarters, leading to higher-than-expected medical costs. UnitedHealth has warned of increased pressure on margins due to greater demand for surgeries, outpatient care, and chronic condition treatments.

3. Public Perception & Legal Risks

Alongside regulatory attention, UnitedHealth is facing public scrutiny. If the DOJ finds grounds for prosecution, the company could face heavy fines, tighter compliance mandates, or even restrictions on future government contracts.

Impact on Investors: What You Should Know

For investors, the combination of legal risk, leadership uncertainty, and financial strain creates a complex risk profile.

Key Concerns:

• Shareholder Value: With shares down over 40% YTD, portfolio exposure is already taking a hit.
  
  
• Earnings Outlook: With the company pulling its 2025 forecast, investors are left without clarity on future earnings potential.
  
  
• Regulatory Uncertainty: Prolonged investigations may drag down sentiment and stock performance even if no wrongdoing is proven.
  
  

While some see the current dip as a buying opportunity in a fundamentally strong company, others warn that further volatility is likely in the coming quarters.

What’s Next: Timeline to Watch

Upcoming Milestones:

• Earnings Report (Early August): Investors are eagerly awaiting the next quarterly results. The focus will be on legal disclosures, medical cost trends, and updated guidance.
  
  
• DOJ Progress Updates: Any new details about the investigation’s scope, possible subpoenas, or charges could further affect stock movement.
  
  
• Organizational Changes: Investors will also watch for more leadership reshuffles or board-level changes aimed at regaining market trust.
  
  

Should You Be Worried?

The UnitedHealth DOJ investigation is a serious matter—not just for the company, but for the broader health insurance industry. While the company has made moves toward transparency and reform, the federal probe introduces significant uncertainty around both earnings and regulatory compliance.

If you’re an investor, this is a moment to remain informed and cautious. Watching how the company navigates the legal, financial, and reputational fallout will be critical in determining whether UnitedHealth can regain its footing—or if deeper troubles lie ahead.

FAQs:

Q1: Why is UnitedHealth under DOJ investigation?
The DOJ is probing UnitedHealth for possibly overbilling Medicare Advantage through inflated diagnoses.

Q2: How did the DOJ probe affect UnitedHealth stock?
UnitedHealth stock fell sharply after the DOJ launched its criminal and civil investigations.